Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373673 | 1.00 | THRA (1.00) | THRATHRB | |
| SCHEMBL8799378 | 0.90 | THRA (0.82) | THRATHRB | |
| SCHEMBL6432405 | 0.89 | THRA (0.80) | THRATHRB | |
| SCHEMBL8798929 | 0.89 | THRA (0.80) | THRATHRB | |
| SCHEMBL8799433 | 0.89 | THRA (0.80) | THRATHRB | |
| SCHEMBL7151397 | 0.87 | THRB (0.77) | THRATHRB | |
| SCHEMBL8799175 | 0.87 | THRA (0.77) | THRATHRB | |
| SCHEMBL8799273 | 0.87 | THRA (0.77) | THRATHRB | |
| SCHEMBL6903277 | 0.87 | THRA (0.77) | THRATHRB | |
| SCHEMBL8798722 | 0.86 | THRA (0.76) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| US-9328331-B2 | Compositions and methods for promoting beta cell maturity | JOSLIN DIABETES CENTER, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20120141436-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010135639-A2 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| EP-0831769-B2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | LAVIN DR THOMAS N (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1036564-B1 | Thyromimetic antiobesity agents | PFIZER PROD INC (US) | 2004-11-17 | — | — | EP | claimed |
| US-6555578-B2 | Kits; containing a compound containing an oxamic acid group | PFIZER INC. | 2003-04-29 | — | — | US | claimed |
| US-20020035153-A1 | Thyromimetic antiobesity agents | CORNELIUS PETER (US) | 2002-03-21 | — | — | US | claimed |
| US-6344481-B1 | Thyromimetic antiobesity agents | PFIZER INC. | 2002-02-05 | — | — | US | claimed |
| EP-1036564-A1 | Thyromimetic antiobesity agents | Pfizer Products Inc. (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0580550-B1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA GEIGY AG (CH) | 1997-10-22 | — | — | EP | claimed |
| US-5569674-A | ANTICHOLESTEROL AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-10-29 | — | — | US | claimed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | claimed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | claimed |
| JP-6172275-A | — | — | None | — | — | JP | disclosed |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260053859-A1 | GENETICALLY ENGINEERED CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-02-26 | — | — | US | disclosed |
| US-5401772-A | Anticholesterol agents with aromatic amines | CIBA-GEIGY CORPORATION (US) | 1995-03-28 | — | — | US | disclosed |
| JP-H06172275-A | HETEROACETIC AICID DERIVATIVE | CIBA GEIGY AG | 1994-06-21 | — | — | JP | disclosed |
| EP-0580550-A1 | Oxamic acid derivatives as hypocholesteremic agents | CIBA-GEIGY AG (CH) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035153-A1 | Thyromimetic antiobesity agents | GPR119, TRHR, TSHR | THRA 5/4885THRB 6/4885 |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | IAPP, ALPG, PNLIP | THRA 3527/4885THRB 1174/4885 |
| US-12637661-B2 | Methods of enhancing stem cell differentiation into beta cells | IAPP, CBX6, HLA-C | THRA 2843/4885THRB 2197/4885 |
| US-20260053859-A1 | GENETICALLY ENGINEERED CELLS | CD47, IAPP, B2M | THRA 1747/4885THRB 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.